HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Jessica Merrill

Senior Editor

New York, NY
Jessica is a senior editor, contributing most frequently to daily pharmaceutical coverage in Scrip and Pink Sheet. With a lengthy career covering the pharmaceutical sector, she specializes primarily in business and commercial news, launch strategy, M&A and market access issues.

Latest From Jessica Merrill

The 10 US Biosimilar Launches That Could Drive Big Savings By 2027

Biosimilar versions of drugs like Humira, Eylea and Keytruda are among the products that could generate cumulative sales of $129bn over the next five years, according to IQVIA.

Biosimilars US States

Dupixent Succeeds Where Other Biologic Drugs Failed – In COPD

Sanofi and Regeneron could be poised to add another blockbuster indication to the IL-4/IL-13 inhibitor, for chronic obstructive pulmonary disease.

Respiratory Inflammation

Takeda’s High-Dose TYK2 Data Could Set It Apart In Psoriasis

Safety and efficacy data show that as long as Takeda can execute effectively on a Phase III program for TAK-279, the company should be well positioned in the oral psoriasis market.

Immune Disorders Clinical Trials

What Seagen’s Pipeline Will Bring To Pfizer

Seagen’s pipeline includes 11 new molecular entities and would double Pfizer’s early-stage oncology clinical pipeline. A next-generation cytotoxic payload for ADCs is on the way too.

Research & Development Cancer

Novo Nordisk Lowers Some Insulin List Prices, Following Lilly’s Lead

The company will lower the US list price of Levemir, NovoLog and certain other branded insulins by 65-75% and will also lower some unbranded insulin prices effective January 2024. Tresiba is not included.

Metabolic Disorders Pricing Strategies

Weight Watchers Weighs In On Obesity Drugs, Offering Valuable Validation

WW International’s decision to move into pharmaceutical weight management could build commercial momentum for Novo Nordisk’s Wegovy and Lilly’s Mounjaro.

Advertising, Marketing & Sales Launches
See All
UsernamePublicRestriction

Register